Verve Therapeutics, Inc. (VERV)
Jul 25, 2025 - VERV was delisted (reason: acquired by LLY)
11.13
0.00 (0.00%)
Inactive · Last trade price on Jul 24, 2025
Verve Therapeutics Revenue
Verve Therapeutics had revenue of $32.98M in the quarter ending March 31, 2025, with 479.03% growth. This brings the company's revenue in the last twelve months to $59.61M, up 271.44% year-over-year. In the year 2024, Verve Therapeutics had annual revenue of $32.33M with 174.98% growth.
Revenue (ttm)
$59.61M
Revenue Growth
+271.44%
P/S Ratio
16.08
Revenue / Employee
$217,566
Employees
274
Market Cap
994.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.33M | 20.57M | 174.98% |
| Dec 31, 2023 | 11.76M | 9.82M | 505.77% |
| Dec 31, 2022 | 1.94M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVERV News
- 3 months ago - Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PRNewsWire
- 3 months ago - Lilly and Verve announce expiration of Verve tender offer - PRNewsWire
- 4 months ago - VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV - Business Wire
- 4 months ago - Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 4 months ago - Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - WSJ
- 4 months ago - Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - Reuters
- 4 months ago - Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PRNewsWire
- 4 months ago - Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. - Barrons